Stock Analysis
Sanofi (EPA:SAN) Full Year 2024 Results
Key Financial Results
- Revenue: €44.3b (down 3.8% from FY 2023).
- Net income: €5.68b (up 5.2% from FY 2023).
- Profit margin: 13% (up from 12% in FY 2023). The increase in margin was driven by lower expenses.
- EPS: €4.54 (up from €4.31 in FY 2023).
SAN Products In Clinical Trials
- Phase I: 16.
- Phase II: 34.
- Phase III: 26.
SAN Post-Clinical Trial Products
- Pre-registration: 7.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sanofi Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 6.1%. Earnings per share (EPS) also missed analyst estimates by 22%.
The primary driver behind last 12 months revenue was the United States segment contributing a total revenue of €20.0b (45% of total revenue). The largest operating expense was General & Administrative costs, amounting to €9.18b (36% of total expenses). Explore how SAN's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in France.
Performance of the French Pharmaceuticals industry.
The company's shares are up 3.0% from a week ago.
Risk Analysis
It is worth noting though that we have found 1 warning sign for Sanofi that you need to take into consideration.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:SAN
Sanofi
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
